HealthWarehouse.com Reports Full Year 2025 Results
Record year for prescriptions processed and cash generated from operations
The Company reported net income of
HealthWarehouse.com, a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (NABP). HealthWarehouse.com provides a platform focused on increasing access to and reducing costs of healthcare products for consumers and business partners nationwide.
Joseph Peters, President and CEO, commented, “2025 was a record year for the Company for total sales and prescriptions processed, while generating record cash from operations. We were able to report net income and positive cash flow by leveraging our prior investments in infrastructure. Our financial results for the past two years, during which our sales have increased
“As we said in our third-quarter release in November, our sales of compounded versions of certain GLP-1 prescription medications were declining. Despite slower growth, we generated positive cash flow during the fourth quarter. Additionally, we are optimistic about new product launches that will allow us to continue to serve longstanding partners, and we are focused on adding partners via our new-business pipeline,” Peters said.
HealthWarehouse.com continues to invest in proprietary technology to remain at the forefront of new developments and offerings in the world of healthcare, focusing on patient experience, operational efficiency, and scalability.
Peters added, “Our success would not be achievable without our dedicated employees, who are committed to our mission of providing world-class service to our customers. I truly appreciate their dedication.”
The Company also announced that it will hold its Annual Meeting of Shareholders virtually on May 12, 2026. Shareholders of record as of March 13, 2026, will receive notice of the meeting and instructions for participating in proxy materials to be distributed soon.
2025 Annual Overview
Net Sales: Net sales increased from
Our authority to dispense high-dollar compounded GLP-1 medications has ended this year. That will have a significant impact on our sales in 2026, and beyond until that volume can be replaced with new partners and expansion of the catalogs of our existing partners. The Company currently expects positive cash from operations during 2026.
Gross Profit: Cost of sales was
Operating Expenses: Selling, general and administrative (SG&A) expenses totaled
Net Income and Adjusted EBITDA: Net income of
2025 Fourth Quarter Overview
Net Sales: Total net sales were
Gross Profit: Gross profit for the fourth quarter of 2025 was
Operating Expenses: Operating expenses were
Net Income and (non-GAAP) Adjusted EBITDA: The Company reported a net loss of
| HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS (Audited) | |||||||||||||||
| For the Three Months Ended | For the Twelve Months Ended | ||||||||||||||
| December 31, | December 31, | ||||||||||||||
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
| Dollars in thousands | |||||||||||||||
| Net sales | $ |
9,852 |
|
$ |
13,703 |
|
$ |
48,994 |
|
$ |
33,614 |
|
|||
| Cost of sales |
|
6,010 |
|
|
9,285 |
|
|
31,852 |
|
|
19,489 |
|
|||
| Gross profit |
|
3,842 |
|
|
4,418 |
|
|
17,142 |
|
|
14,125 |
|
|||
| Selling, general and administrative expenses |
|
3,951 |
|
|
4,202 |
|
|
16,730 |
|
|
14,218 |
|
|||
| Net income (loss) from operations |
|
(109 |
) |
|
216 |
|
|
412 |
|
|
(93 |
) |
|||
| Other expense | |||||||||||||||
| Loss on extinguishment of debt |
|
- |
|
|
- |
|
|
- |
|
|
(3 |
) |
|||
| Interest expense |
|
(21 |
) |
|
(27 |
) |
|
(72 |
) |
|
(237 |
) |
|||
| Income (loss) before taxes |
|
(130 |
) |
|
189 |
|
|
340 |
|
|
(333 |
) |
|||
| Income tax expense |
|
61 |
|
|
- |
|
|
(75 |
) |
|
- |
|
|||
| Net income (loss) |
|
(69 |
) |
|
189 |
|
|
265 |
|
|
(333 |
) |
|||
| . | |||||||||||||||
| Preferred stock: | |||||||||||||||
| Series B convertible contractual dividends |
|
(86 |
) |
|
(86 |
) |
|
(342 |
) |
|
(342 |
) |
|||
| Net income (loss) attributable to common stockholders | $ |
(155 |
) |
$ |
103 |
|
$ |
(77 |
) |
$ |
(675 |
) |
|||
| Per share data: | |||||||||||||||
| Net income (loss) - basic | $ |
(0.00 |
) |
$ |
0.00 |
|
$ |
0.00 |
|
$ |
(0.01 |
) |
|||
| Net income (loss) - diluted | $ |
(0.00 |
) |
$ |
0.00 |
|
$ |
0.00 |
|
$ |
(0.01 |
) |
|||
| Series B convertible contractual dividends | $ |
(0.00 |
) |
$ |
(0.00 |
) |
$ |
(0.01 |
) |
$ |
(0.01 |
) |
|||
| Net income (loss) attributable to common stockholders - basic | $ |
(0.00 |
) |
$ |
0.00 |
|
$ |
(0.00 |
) |
$ |
(0.01 |
) |
|||
| Net income (loss) attributable to common stockholders - diluted | $ |
(0.00 |
) |
$ |
0.00 |
|
$ |
(0.00 |
) |
$ |
(0.01 |
) |
|||
| Weighted average common shares outstanding - basic (In thousands) |
|
56,734 |
|
|
55,573 |
|
|
56,348 |
|
|
55,186 |
|
|||
| Weighted average common shares outstanding - diluted (in thousands) |
|
56,734 |
|
|
91,832 |
|
|
56,348 |
|
|
55,186 |
|
|||
Use of Non-GAAP Financial Measures
HealthWarehouse.com, Inc. (the "Company") prepares its consolidated financial statements in accordance with
Adjusted EBITDA should not be considered as an alternative to net income, net loss, or to net cash provided by or used in operating activities, as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the Company`s performance.
Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP)
| Three Months Ended | Twelve Months Ended | |||||||||||||
| December 31, | December 31, | |||||||||||||
|
2025 |
|
|
2024 |
|
2025 |
|
2024 |
|
|||||
| Dollars in thousands | ||||||||||||||
| Net income (loss) | $ |
(69 |
) |
$ |
189 |
$ |
265 |
$ |
(333 |
) |
||||
| Interest expense |
|
21 |
|
|
27 |
|
72 |
|
237 |
|
||||
| Income tax expense |
|
(61 |
) |
|
- |
|
75 |
|
- |
|
||||
| Depreciation and amortization |
|
135 |
|
|
119 |
|
519 |
|
434 |
|
||||
| EBITDA (non-GAAP) |
|
26 |
|
|
335 |
|
931 |
|
338 |
|
||||
| Adjustments to EBITDA: | ||||||||||||||
| Stock-based compensation |
|
163 |
|
|
188 |
|
661 |
|
750 |
|
||||
| Loss on extinguishment of debt |
|
- |
|
|
- |
|
- |
|
3 |
|
||||
| Adjusted EBITDA | $ |
189 |
|
$ |
523 |
$ |
1,592 |
$ |
1,091 |
|
||||
About HealthWarehouse.com
HealthWarehouse.com, Inc. (OTCQB: HEWA), a technology company with a focus on healthcare e-commerce, sells and delivers prescription and over-the-counter medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (“NABP”). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers and business partners nationwide. Based in
Forward-Looking Statements
This announcement and the information incorporated by reference herein contain “forward-looking statements” as defined in federal securities laws, including but not limited to Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which statements are based on our current expectations, estimates, forecasts and projections. Statements that are not historical facts, including statements about the beliefs, expectations and future plans and strategies of the Company, are forward-looking statements. Actual results may differ materially from those expressed in forward looking statements or in management's expectations. Important factors which could cause or contribute to actual results being materially and adversely different from those described or implied by forward looking statements include, among others, risks related to competition, management of growth, access to sufficient capital to fund our business and our growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, cyber-attacks, access to sufficient inventory, government regulation and taxation and fraud. More information about factors that potentially could affect HealthWarehouse.com's financial results is included in HealthWarehouse.com's audited Annual Reports and Quarterly Reports available at otcmarkets.com and prior filings with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260320532120/en/
Dan Seliga, Chief Financial Officer, (800) 748-7001
Source: HealthWarehouse.com, Inc.
